
Pregnant doctor denied Covid-19 vaccine sues Trump administration
The lawsuit specifically takes aim at health secretary Robert F Kennedy's unilateral decision to recommend against Covid-19 vaccines for pregnant women and healthy children.
Kennedy's announcement circumvented expert scientific review panels and flouted studies showing pregnant women are at heightened risk from the virus, and made it more difficult for some to get the vaccine.
'This administration is an existential threat to vaccination in America, and those in charge are only just getting started,' said Richard H Hughes IV, partner at Epstein Becker Green and lead counsel for the plaintiffs in a statement.
The American Academy of Pediatrics, American College of Physicians and American Public Health Association are among a list of leading physicians associations named as plaintiffs in the lawsuit.
'If left unchecked, secretary Kennedy will accomplish his goal of ridding the United States of vaccines, which would unleash a wave of preventable harm on our nation's children,' said Hughes. 'The professional associations for pediatricians, internal medicine physicians, infectious disease physicians, high-risk pregnancy physicians, and public health professionals will not stand idly by as our system of prevention is dismantled. This ends now.'
In late May, Kennedy announced that the Centers for Disease Control and Prevention (CDC) would no longer recommend Covid-19 vaccines for healthy children or pregnant women. The announcement, made on social media, contradicted a raft of evidence showing pregnant women and infants are at especially high-risk from the disease, including from the administration's own scientific leaders.
In June, Kennedy went further by firing all 17 sitting members of a key vaccine advisory panel to the CDC. The advisory panel is a key link in the vaccine distribution pipeline, helping to develop recommendations insurers use when determining which vaccines to cover.
That panel met for the first time in late June. Members announced they would review both the childhood vaccine schedule and any vaccines that had not been formally reviewed in seven years. They also recommended against a long-vilified vaccine preservative, in spite of a lack of evidence of harm.
The news comes amid the largest annual measles case count in 33 years, and amid reports of more parents seeking early vaccination for their children, fearing vaccines will go into shortage or no longer be covered by insurance.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
23 minutes ago
- Reuters
Drugmaker Biogen to invest $2 billion more in North Carolina
July 21 (Reuters) - Biogen (BIIB.O), opens new tab will invest an additional $2 billion in its existing manufacturing in North Carolina, the drugmaker said on Monday, as it seeks to expand its presence in the U.S. amid President Donald Trump's tariff threats. The company said the investment will go to its manufacturing plants in North Carolina's Research Triangle Park (RTP), which produce its major therapies for multiple sclerosis and Alzheimer's. Biogen has invested about $10 billion in its North Carolina manufacturing to date. The drugmaker said it plans to continue investing in multiple modalities and factories across its two campuses in RTP.


Reuters
23 minutes ago
- Reuters
FDA appoints George Tidmarsh as top drug regulator
July 21 (Reuters) - U.S. Food and Drug Administration commissioner Marty Makary has appointed former biotech executive George Tidmarsh as the director of the Center for Drug Evaluation and Research, the health regulator said on Monday.


Reuters
an hour ago
- Reuters
FDA to appoint George Tidmarsh as top drug regulator, Bloomberg News reports
July 21 (Reuters) - U.S. Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the director of the Center for Drug Evaluation and Research, Bloomberg News reported on Monday, citing a person familiar with the decision. Tidmarsh's appointment as the agency's top drug regulator could be announced as soon as Monday, the report said, citing the person who asked not to be identified. The Department of Health and Human Services, which oversees the FDA, did not immediately respond to a Reuters request for comment. Tidmarsh also did not immediately respond to email and LinkedIn requests for comment.